<DOC>
	<DOCNO>NCT00258050</DOCNO>
	<brief_summary>To characterize effect repeat oral dose lapatinib treatment pharmacokinetics single oral single intravenous dose midazolam adult cancer patient . Also assess safety tolerability chronic oral lapatinib therapy cancer patient .</brief_summary>
	<brief_title>To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Inclusion criterion : Histologically confirm , solid tumor refractory standard therapy . Tumor standard therapy . Able swallow retain oral medication . ECOG ( Eastern Cooperative Oncology Group ) performance status 0 2 . Provided write informed consent . Adequate bone marrow function . Serum creatinine less equal 1.5 mg/dL . Calculated creatinine clearance great equal 60 ml/min base Cockcroft Gault . Total bilirubin great equal upper limit normal institutional value . Aspartate alanine transaminase less equal 3 time upper limit institutional value . Have leave ventricular ejection fraction ( LVEF ) great equal 40 % base electrocardiogram ( ECHO ) multiple gated acquisition scan ( MUGA ) . Resting oxygen saturation great 90 % . Exclusion criterion : Pregnant lactate female . Have malabsorption syndrome , disease affect gastrointestinal function . Resection stomach small bowel . Evidence symptomatic uncontrolled brain metastasis leptomeningeal disease . Is consider medically unfit study investigator result medical interview , physical exam , screen investigation . Have know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate investigational product . Use anilinoquinazolines , gefitinib [ Iressa™ ] , erlotinib [ Tarceva™ ] . Immediate delay hypersensitivity reaction midazolam component formulation , include benzyl alcohol ( crosssensitivity benzodiazepine may exist ) . Has narrowangle glaucoma contraindication midazolam use . Has receive treatment investigational drug previous 4 week . Received chemotherapy , immunotherapy , biologic therapy hormonal therapy within past 14 day , exception mitomycin C within past 6 week . Currently receive amiodarone receive amiodarone 6 month prior screen . Is take regular dos opiates opinion investigator would put patient risk clinically significant respiratory compromise midazolam administer . Physiological , familial , sociological , geographical condition permit compliance protocol . Has Class II IV heart failure define New York Heart Association ( NYHA ) functional classification system . Clinically significant electrocardiogram ( ECG ) abnormality . Clinically assess inadequate venous access protocolrelated blood draw .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>lapatinib</keyword>
	<keyword>midazolam</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>